BlackRock’s Edgewise Therapeutics EWTX Stock Holding History
Bought
Maintained
Sold
Other funds holding EWTX
BBA
SL
BlackRock's EWTX Position: Q3 2026 in Review
BlackRock increased its Edgewise Therapeutics (EWTX) stake by 10% in Q3 2026, buying an estimated $28.4M and bringing the position to 7,274,226 shares worth $295M. The position accounts for ﹤0.01% of the portfolio, ranked #1542.
BlackRock first reported a position in EWTX in Q1 2021 and has held it in 23 quarters since. 253 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.
- BlackRock held 7,274,226 shares of Edgewise Therapeutics worth $295M as of Q3 2026.
- BlackRock bought 667,890 Edgewise Therapeutics shares in Q3 2026, an estimated $28.4M.
- Edgewise Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #1542 holding.
- BlackRock first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 23 quarters since.
- 253 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.
Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.